Evogene (EVGN) Other Working Capital Changes (2013 - 2026)
Evogene (EVGN) posted Other Working Capital Changes of -$121000.0 for Q1 2026, up 9.02% sequentially from -$133000.0 in Q4 2025, and up 17.12% YoY from -$103309.9 in Q1 2025.
Evogene (EVGN) Other Working Capital Changes (2013 - 2026) Analysis & Trends
Evogene has reported Other Working Capital Changes for 14 years, with the latest figure at -$121000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 17.12% year-over-year to -$121000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$501000.0 (up 37.14% YoY) and the FY2025 annual result came in at -$526000.0, up 40.63% from the prior year.
- Other Working Capital Changes grew to -$121000.0 in Q1 2026 per EVGN's latest filing, from -$133000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.5 million in Q1 2025 and troughed at -$437000.0 in Q2 2024.
- A 5-year average of -$186352.9 and a median of -$206000.0 in 2023 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes surged 204.13% in 2022, then slumped 267.46% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$437000.0 in 2022, then jumped by 51.49% to -$212000.0 in 2023, then plunged by 46.23% to -$310000.0 in 2024, then jumped by 57.1% to -$133000.0 in 2025, then advanced by 9.02% to -$121000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$121000.0, -$133000.0, and -$110000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121,000.00 |
| Mar 31, 2026 | -121,000.00 |
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | -133,000.00 |
| Dec 31, 2025 | -133,000.00 |
| Dec 31, 2025 | -133,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Jun 30, 2025 | -137,000.00 |
| Jun 30, 2025 | -137,000.00 |
| Jun 30, 2025 | -137,000.00 |
| Mar 31, 2025 | -146,000.00 |
| Mar 31, 2025 | -146,000.00 |
| Mar 31, 2025 | -146,000.00 |
| Dec 31, 2024 | -310,000.00 |
| Dec 31, 2024 | -310,000.00 |
| Dec 31, 2024 | -310,000.00 |
| Sep 30, 2024 | -106,000.00 |
| Sep 30, 2024 | -106,000.00 |